Study Highlights:
- Combining the anti-blood clot medicine clopidogrel (Plavix) with aspirin is unlikely to prevent recurrent small subcortical strokes, which are caused by blood clots deep in the middle of the brain.
- The combination treatment yielded higher bleeding and death rates compared to aspirin alone.
- Due to these preliminary results, researchers stopped the study early.
NEW ORLEANS, Feb. 3, 2012 (GLOBE NEWSWIRE) -- The anti-blood clot regimen that adds the drug clopidogrel (Plavix) to aspirin treatment is unlikely to prevent recurrent strokes and may increase the risk of bleeding and death in patients with subcortical stroke according to late-breaking research presented at the American Stroke Association's International Stroke Conference 2012.
Because of these preliminary results, researchers ended the anti-clotting part of the Secondary Prevention of Small Subcortical Strokes Trial (SPS3) in August 2011. The part of the study that examines the effect of high blood pressure treatments will continue. The SPS3 trial is the first large-scale study of patients with subcortical strokes, which occur when small blood vessels deep in the middle of the brain are blocked, damaging small areas of brain tissue. This type of stroke affects about 150,000 Americans each year, and is the most common cause of vascular dementia according to Oscar Benavente, M.D., lead author of the study and a professor of neurology at Canada's University of British Columbia in Vancouver, British Columbia.
American Heart Association/American Stroke Association guidelines for preventing recurrent strokes recommend anti-clotting medications like aspirin, the customary treatment, or other clot preventives like clopidogrel, but not the combination of aspirin plus clopidogrel.
Treatments have not been compared in patients with subcortical strokes specifically.
In the United States, stroke is the No. 4 killer and a leading cause of disability among adults.
Beginning in March 2003, the SPS3 study included 3,020 patients at 81 sites in the United States, Canada, Spain, Mexico and South America. Stroke patients were randomly assigned within 180 days of symptom onset to receive aspirin and clopidogrel or aspirin plus placebo daily. Neither researchers nor patients knew who received placebo or the study drug.
Preliminary findings showed that the risk of bleeding nearly doubled among patients on the clopidogrel/aspirin combination, compared to those on aspirin and placebo: Aspirin plus placebo had a 1.1 percent of bleeding risk per year and aspirin plus clopidogrel a 2.1 percent bleeding risk per year – largely from major bleeds somewhere other than in the brain.
Similarly, the annual risk of death was greater with the combined therapy: Aspirin plus placebo had a 1.4 percent risk of death and aspirin plus clopidogrel had a 2.1 percent risk of death.
There was no difference in stroke recurrence in both treatment arms.
"These interim results do not support the use of combination clopidogrel plus aspirin for secondary stroke prevention in patients with small subcortical strokes," the researchers said.
Co-investigator is Robert G. Hart, M.D. Author disclosures are on the abstract.
The National Institutes of Health, National Institute of Neurological Diseases and Stroke, funded the study.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing science content. Revenues from pharmaceutical and device corporations are available at www.heart.org/corporatefunding.
###
NR12-1026 (ISC 2012/Benavente)
(Note: Actual presentation is 12:12 p.m. CT Friday, Feb. 3, 2012.)
Additional resources:
- All downloadable video/audio interviews, B-roll, animation and images related to this news release are located on the right column of the release link located at http://newsroom.heart.org/pr/aha/_prv-clopidogrel-with-aspirin-doesn-228204.aspx
- General ISC video and ISC photos available at newsroom.heart.org/ISC12-Video or newsroom.heart.org/ISC12-Photos.
- Follow news from ASA International Stroke Conference 2012 via Twitter: http://twitter.com/#!/heartnews. Follow #ASANews12.
Media Contacts:
ASA News Media Office in Dallas: (214) 706-1396
ASA News Media Office in New Orleans, Feb. 1-3: (504) 670-6010
For Public Inquiries: (800) AHA-USA1 (242-8721)